Male Breast Carcinoma (DBCOND0030384)

Identifiers

Synonyms

Carcinoma of Male Breast / Cancer of male breast / Malignant neoplasm of male breast (disorder) / Carcinoma of male breast (disorder) / Breast cancer male / Male Breast Cancer / Breast cancer male NOS

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT02393105	Sense of Hope Alleviates Fatigue in Breast Cancer Survivors	No drug interventions	Not Available	Not Available	unknown_status
NCT00770809	Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery	Lapatinib Paclitaxel Trastuzumab	treatment	3	active_not_recruiting
NCT06422455	Access to Genetic Testing in Underserved Patients With Cancer	No drug interventions	health_services_research	Not Available	not_yet_recruiting
NCT00450879	Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery	Pazopanib	treatment	1	terminated
NCT00861705	Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery	Bevacizumab Carboplatin Cyclophosphamide Doxorubicin Paclitaxel	treatment	2	active_not_recruiting
NCT00070252	Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer	Capecitabine Docetaxel Tipifarnib	treatment	1 / 2	completed
NCT01131234	Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors	Cediranib RG-4733	treatment	1	completed
NCT01276496	Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery	Cilengitide Paclitaxel	treatment	1	completed
NCT01928186	FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer	Alovudine F-18	diagnostic	Not Available	completed
NCT01145430	Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer	Doxorubicin Tetracycline Veliparib	treatment	1	completed
NCT00699491	Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer	Cixutumumab Menthol Sirolimus Temsirolimus	treatment	1 / 2	completed
NCT01149356	RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer	Exemestane Goserelin RG-4733	treatment	1	terminated
NCT01349959	Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer	Azacitidine Entinostat	treatment	2	active_not_recruiting
NCT01624441	Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer	Dinaciclib Epirubicin	treatment	1	completed
NCT02206334	Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer	No drug interventions	treatment	1	completed
NCT00118157	Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen	Lapatinib Tamoxifen	treatment	2	completed
NCT01281150	Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors	Carboplatin Paclitaxel Veliparib	treatment	1	completed